These data indicate that, for suppression of viral relapse, the treatment effect of Peg-IFN/ribavirin is important, because hepatic fibrosis, IL28B genotype, and age have previously been reported as factors affecting SVR in Peg-IFN/ribavirin therapy (Tanaka et al. 2009; Manns et al. 2001; Fried et al. 2002; Dienstag and McHutchison 2006). The gene discussed is IFNA1; the disease is Hepatic fibrosis.